Actively Recruiting
Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
Led by Emory University · Updated on 2026-02-11
200
Participants Needed
2
Research Sites
424 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This clinical trial evaluates the influenza virus vaccination in evaluating human immune response in patients with lymphoma. Evaluating immune response may increase the understanding of how the immune system changes when patients receive treatment for lymphomas by looking at the antibody levels and the level of the different cells that make up the immune system over time compared to those without lymphoma.
CONDITIONS
Official Title
Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of lymphoma including B-cell non-Hodgkin lymphoma (B-NHL) with at least 1 cycle of chemotherapy received
- B-NHL in complete remission within 12 months after chemotherapy or for over 12 months
- Chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL) patients receiving ibrutinib for at least 1 month
- Aggressive peripheral T-cell lymphoma (PTCL) patients with at least 1 cycle of chemotherapy
- Ability to provide written or electronic informed consent and comply with study visits
- Screening blood tests within acceptable ranges for hemoglobin (7.0-16.1 gm/dL) and platelet count (10-600/µL)
- For cohort 1, no seasonal influenza vaccine received or suspected influenza infection during current flu season
- For cohort 3, previous receipt of at least 1 dose of SARS-CoV2 vaccine or eligibility for enrollment if not previously vaccinated
You will not qualify if you...
- Known HIV infection
- Any medical condition that poses unacceptable risk or interferes with study participation, including chronic diseases lasting 3 months or more
- Acute illness within 72 hours before vaccination, unless symptoms are minor and not from influenza
- Use of long-term systemic steroids (>3 months in past 12 months)
- Known allergy to eggs, egg or chicken protein, or vaccine components
- History of Guillain-Barre syndrome (GBS)
- Suspected or confirmed influenza infection during current flu season
- Abnormal vital signs or physical exam at screening (fever ≥38.0°C, abnormal blood pressure, pulse, new rash, infection signs)
- Receipt of seasonal influenza vaccine in current vaccination season
- Enrollment in hospice or life expectancy less than 6 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Emory University Hospital Midtown
Atlanta, Georgia, United States, 30308
Actively Recruiting
2
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, United States, 30322
Actively Recruiting
Research Team
A
Andres Chang, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here